Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00376857 |
Recruitment Status :
Completed
First Posted : September 15, 2006
Last Update Posted : September 15, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Idiopathic Epiretinal Membrane, Cataract | Drug: Surgery with and without the aid of Indocyanine Green (ICG) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single |
Primary Purpose: | Treatment |
Official Title: | Surgical Removal of Idiopathic Epiretinal Membrane With and Without the Assistance of Indocyanine Green: a Randomised Controlled Clinical Trial |

- The main outcome measure was improvement of best-corrected visual acuity (BCVA).
- Other outcome measures included postoperative BCVA, status of Amsler grid test, reduction of macular retinal thickness, residual or recurrent macular epiretinal membrane

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with IEM and cataract or posterior chamber intraocular lens pseudophakia complaining of loss of visual acuity and metamorphopsia during the past six months.
Exclusion Criteria:
- Other retinal disease, non-idiopathic epiretinal membrane, glaucoma or history of retinal detachment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00376857
Germany | |
Dept. of Ophthalmology, University of Regensburg | |
Regensburg, Germany, 93042 |
Principal Investigator: | Jost Hillenkamp, MD | Dept. of Ophthalmology, University of Regensburg | |
Principal Investigator: | Parykshit Saikia, MD | Dept. of Ophthalmology, University of Regensburg | |
Study Chair: | Helmut G Sachs, MD | Dept. of Ophthalmology, University of Regensburg |
ClinicalTrials.gov Identifier: | NCT00376857 |
Other Study ID Numbers: |
03123 |
First Posted: | September 15, 2006 Key Record Dates |
Last Update Posted: | September 15, 2006 |
Last Verified: | September 2006 |
Indocyanine green, toxicity, epiretinal membrane, visual field defect |
Cataract Epiretinal Membrane Lens Diseases Eye Diseases Retinal Diseases |